FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology. What is presented is an antibody representing a neutralising VEGFR-2/KDR antibody with its hypervariable regions being identical to the hypervariable regions of TTAC 0001 of VEGFR-2/KDR antibody fused with a binding domain of angiopoietin 2 which is Tie-2 ligand for treating cancer by angiogenesis inhibition. A DNA coding the above antibody, an expression vector containing the above DNA, and a CHO host cell transformed by the above vector for preparing the antibody are also described. What is also presented is a method for preparing the antibody involving: host cell incubation, and the antibody recovery from a culture fluid of CHO cell. What is described is a pharmaceutical composition for treating an angiogenesis-related disease, containing an effective amount of the above antibody and at least one pharmaceutically acceptable carrier.
EFFECT: invention enables preparing the VEGFR-2/KDR antibody fused with the binding domain of angiopoietin 2 which may be used for effective treatment of a disease related to excessive angiogenesis.
13 cl, 10 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST TIE-2 AND ITS USE | 2020 |
|
RU2795455C2 |
| BISPECIFIC BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2011 |
|
RU2597973C2 |
| COMBINATIONS AND COMPOSITIONS EFFECTING ON FUNCTION OF VEGF/VEGF RECEPTOR AND ANGIOPOIETIN/TIE(II) RECEPTOR SYSTEMS AND USES THEREOF | 2001 |
|
RU2292221C2 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| ISOLATED TIE-LIGAND-4 AND ITS ISOLATED FIBRINOGEN-LIKE DOMAIN; ISOLATED NUCLEIC ACID MOLECULE ENCODING INDICATED LIGAND; VECTOR COMPRISING INDICATED NUCLEIC ACID; METHOD FOR PREPARING HOST-CELL TRANSFORMED WITH INDICATED VECTOR; METHOD FOR PREPARING TIE-LIGAND-4; CONJUGATE COMPRISING INDICATED LIGAND; LIGAND-BODY COMPRISING INDICATED FIBRINOGEN-LIKE DOMAIN | 1997 |
|
RU2242514C2 |
| ANTIBODIES AGAINST ANGIOPOIETIN-2 AND USE THEREOF | 2005 |
|
RU2394839C2 |
| HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPBETA), AND USE THEREOF | 2007 |
|
RU2494108C2 |
| METHOD OF TREATING OPHTHALMIC ANGIOGENESIS, RETINAL OEDEMA, RETINAL ISCHEMIA AND DIABETIC RETINOPATHY WITH USING SELECTIVE RTK INHIBITORS | 2006 |
|
RU2445096C2 |
| BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2009 |
|
RU2542382C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
